3 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Maximum Tolerated Dose: new trials by email Literature Review of Maximum Tolerated Dose trials Research Report on Maximum Tolerated Dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-SARS Cov-2 T Cell Infusions for COVID 19 Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs) - SARS-CoV 2, Viral Infection | Phase 1 | Terminated | Baylor College of Medicine | 4 | 2020-11-04 | 2022-12-19 |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC 350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Terminated | CytoDyn, Inc. | 10 | 2019-04-22 | 2025-09-09 |
| A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) Avelumab, M9241, Avelumab (Once weekly) - Advanced Solid Tumors | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 52 | 2017-01-31 | 2024-09-20 |
COVID-19 (1) · Triple Negative Breast Neoplasms (1) · Virus Diseases (1)
Baylor College of Medicine (1) · CytoDyn, Inc. (1) · EMD Serono Research & Development Institute, Inc. (1)
United States (3) · Belgium (1) · France (1) · Hungary (1) · Italy (1) · Netherlands (1) · Spain (1)
Jacob Lalezari, MD (1) · Premal Lulla (1)
2017 (1)